DME in the Real World: Treatments Past, Present, and Future Pre-test

The Diabetic Retinopathy Clinical Research Network (DRCR) Protocol T study is important because:
Corticosteroids as a treatment for DME:
In the Reinforce Study what is the mean number of Dexamethasone implant injections given per year?
In the EARLY Study what percent of reduction in Central Retinal Thickness (CRT), after three injections was predictive of visual response at three years?
Based on the Open Label Extension study and the ENDURANCE extension study following the Phase III RIDE/RISE and VISTA/VIVID trials analyzing ranibizumab and aflibercept for DME management respectively, the mean number of anti-VEGF treatments administered in the 4th year of treatment was:
In the Clinical Trial Examining Patient Appointment Compliance Trends?
A 73 year old female, diagnosed with type 2 diabetes 14 years ago, presents with DME OD and 20/80 vision. She is started on Anti-VEGF medication and after each injection her edema decreases and vision improves. However the retina remains dry for approximately one month which causes the edema to return and her vision to decrease. The swelling reoccurred and she was scheduled for anti-VEGF injections. The patient missed her appointment due to a trip to the emergency room where she reported her face sagged for 4 hours. At this time ER doctors were unsure if the cause was TIA or mild CVA. What would you do?